Regeneron is one of the few drugmakers to have successfully developed a treatment for an outbreak, and it's ahead of schedule on Covid-19. The first two trials of Regeneron’s new coronavirus drug will look at whether REGN-COV2 works as a treatment for hospitalized and non-hospitalized patients. Regeneron has been at the forefront of the COVID-19 fight for months with partnered med Kevzara in clinical trials and an antibody cocktail in development. REGN's dividend yield, history, payout ratio, proprietary DARS™ rating & much more! Biotech behemoth Regeneron is gearing up to have a potential “cocktail” drug — to both prevent and treat the novel coronavirus — ready for human clinical trials by early this summer.

The … Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Regeneron Limerick, Raheen, is making major advancements in developing a drug for Covid-19, through the isolation of hundreds of antibodies. Regeneron is the first company thus far to advance a cocktail of two engineered antibodies into clinical testing, although both Lilly and AstraZeneca are also planning to take a combination approach. I consider to be Regeneron a buy right now because it has ample opportunity to increase the revenue and profits it currently generates from its three key drugs, Eylea, Dupixent, and Libtayo. Regeneron and its partner, Sanofi, are evaluating rheumatoid arthritis drug Kevzara in a phase 2/3 clinical study for treating patients who develop severe cases of COVID-19. Regeneron, which has its Irish headquarters in Raheen, employs over 1000 people in Limerick alone. Regeneron Pharmaceuticals is on deck to launch several drugs with blockbuster potential over the next few years, including a skin cancer treatment in 2018, an analyst predicted Thursday. Regeneron used a similar strategy to develop a three-drug antibody combination for Ebola that is currently under Food and Drug Administration review.

Regeneron Pharmaceuticals this week initiated test trials of an arthritis drug as a potential remedy for the worst symptoms of COVID-19 in hopes of confirming studies in China.

Dividend.com: The #1 Source For Dividend Investing.